Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious dise… Read more
Revive Therapeutics Ltd (RVVTF) - Total Assets
Latest total assets as of December 2024: $9.72 Million USD
Based on the latest financial reports, Revive Therapeutics Ltd (RVVTF) holds total assets worth $9.72 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Revive Therapeutics Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Revive Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Revive Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2024)
Revive Therapeutics Ltd's total assets of $9.72 Million consist of 10.7% current assets and 89.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.38 Million | 88.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Revive Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revive Therapeutics Ltd's current assets represent 10.7% of total assets in 2024, a decrease from 95.0% in 2014.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2024, down from 88.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 4.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 88.2% of total assets.
Revive Therapeutics Ltd Competitors by Total Assets
Key competitors of Revive Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Revive Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Revive Therapeutics Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Revive Therapeutics Ltd is currently not profitable relative to its asset base.
Revive Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.31 | 0.92 |
| Quick Ratio | 0.06 | 0.31 | 0.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.04 Million | $ -2.22 Million | $ -74.37K |
Revive Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Revive Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | -25.4% |
| Total Assets | $10.64 Million |
| Market Capitalization | $5.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Revive Therapeutics Ltd's assets below their book value (0.53 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Revive Therapeutics Ltd's assets decreased by 25.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Revive Therapeutics Ltd (2014–2024)
The table below shows the annual total assets of Revive Therapeutics Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $10.64 Million | -25.37% |
| 2023-06-30 | $14.25 Million | -16.49% |
| 2022-06-30 | $17.07 Million | -42.75% |
| 2021-06-30 | $29.81 Million | +260.83% |
| 2020-06-30 | $8.26 Million | +544.07% |
| 2019-06-30 | $1.28 Million | +14.47% |
| 2018-06-30 | $1.12 Million | -41.76% |
| 2017-06-30 | $1.92 Million | +38.69% |
| 2016-06-30 | $1.39 Million | -47.98% |
| 2015-06-30 | $2.67 Million | +111.86% |
| 2014-06-30 | $1.26 Million | -- |